---
title: "Fudan Zhangjiang Invests RMB210 Million in Low-Risk SPD Bank Structured Deposit"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/281907995.md"
description: "Shanghai Fudan Zhangjiang Bio Pharmaceutical Co. has invested RMB210 million in a low-risk structured deposit with SPD Bank. The deposit offers a floating annualized return of 0.70% to 2.05% over 87 days, linked to the EUR/USD exchange rate. This transaction exceeds 5% but is below 25% of applicable percentage ratios, requiring disclosure but not shareholder approval. The investment aims to optimize short-term liquidity while maintaining principal security, reflecting the company's strategy to manage idle funds through conservative financial products."
datetime: "2026-04-07T11:18:13.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/281907995.md)
  - [en](https://longbridge.com/en/news/281907995.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/281907995.md)
---

# Fudan Zhangjiang Invests RMB210 Million in Low-Risk SPD Bank Structured Deposit

### Easter Sale - 70% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Shanghai Fudan Zhangjiang Bio Pharmaceutical Co ( (HK:1349) ) has provided an update.

Shanghai Fudan Zhangjiang Bio Pharmaceutical Co. has entered into an agreement with SPD Bank to subscribe to a principal-guaranteed corporate structured deposit product using RMB210 million of idle funds from its daily operations. The product, assessed as low risk by SPD Bank, offers a floating annualized return between 0.70% and 2.05% over an 87-day term and is linked to the EUR/USD exchange rate, with no early redemption right for the company but allowing early termination by the bank under certain circumstances.

The transaction size triggers disclosable transaction requirements under Hong Kong listing rules, as one or more applicable percentage ratios exceed 5% but remain below 25%. As a result, the deal must be reported and announced but does not require shareholder approval, signaling that the company is optimizing short-term liquidity via relatively conservative financial products without materially altering its risk profile or capital structure.

**More about Shanghai Fudan Zhangjiang Bio Pharmaceutical Co**

Shanghai Fudan Zhangjiang Bio Pharmaceutical Co. operates in the biopharmaceutical industry, focusing on the research, development and commercialization of drug products. The company generates sufficient operating cash to accumulate idle funds, which it actively manages through low-risk financial instruments to enhance capital efficiency while maintaining principal security.

**Average Trading Volume:** 1,760,282

**Current Market Cap:** HK$968.2M

Learn more about 1349 stock on TipRanks’ Stock Analysis page.

### Related Stocks

- [688505.CN](https://longbridge.com/en/quote/688505.CN.md)
- [600000.CN](https://longbridge.com/en/quote/600000.CN.md)
- [01349.HK](https://longbridge.com/en/quote/01349.HK.md)

## Related News & Research

- [XtalPi’s QuantumPharm Commits RMB356 Million to Low-Risk SPDB Structured Deposits](https://longbridge.com/en/news/285219185.md)
- [Fudan-Zhangjiang Deploys RMB110 Million in Low-Risk Structured Deposits](https://longbridge.com/en/news/271770137.md)
- [OPC Energy Reports Strong First Quarter 2026 Financial Results](https://longbridge.com/en/news/287057775.md)
- [ZAWYA: Al Habtoor Tower: Dubai's boldest residential project yet](https://longbridge.com/en/news/287051508.md)
- [PRECIOUS-Gold falls with MidEast war in focus after Trump pauses strike](https://longbridge.com/en/news/286878933.md)